By inhibiting FGFR3, anlotinib blocks downstream signaling pathways, such as the RAS/RAF/MEK/ERK and PI3K/AKT pathways, which are crucial for tumor growth and survival. The gene discussed is MAP2K7; the disease is neoplasm.